Lenzilumab

Timothy Morris Joins Humanigen as Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Monday, August 3, 2020
Other Communications, Other Manufacturing, Public relations, Investor relations, Other Transport, Communications, Logistics, Supply chain management, Manufacturing, Transport, Other Health, Other Science, Pharmaceutical, Research, Other Retail, Oncology, Infectious diseases, Genetics, Clinical trials, Retail, Other Professional Services, Science, Biotechnology, Human resources, General Health, Finance, Health, Supply chain management, Professional services, Medical specialties, Branches of biology, Immunology, Clinical medicine, Monoclonal antibodies, Cytokines, Lenzilumab, Growth factors, Granulocyte-macrophage colony-stimulating factor, Cytokine release syndrome, Cytokine, Colony-stimulating factor

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.
  • Mr. Morris has more than two decades of experience serving in executive roles at public biotechnology companies.
  • He most recently served as Chief Financial Officer of Iovance, leading the companys raise of over $1 billion in equity, including a recent $600 million secondary offering.
  • Mr. Morris has been a member of the Humanigen Board of Directors since 2016.

National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial

Retrieved on: 
Monday, July 27, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Health, Organic compounds, Drugs, Antivirals, COVID-19, Nitriles, Nucleotides, Remdesivir, Coronavirus disease, Lenzilumab, COVID-19 drug development, Draft:Sarah Pett

This trial builds on initial data from NIAIDs Adaptive COVID-19 Treatment Trial (ACTT) that demonstrated Gileads investigational antiviral, remdesivir, may improve time to recovery in hospitalized patients with COVID-19.

Key Points: 
  • This trial builds on initial data from NIAIDs Adaptive COVID-19 Treatment Trial (ACTT) that demonstrated Gileads investigational antiviral, remdesivir, may improve time to recovery in hospitalized patients with COVID-19.
  • BET will evaluate the combination of lenzilumab and remdesivir on treatment outcomes versus placebo and remdesivir in hospitalized COVID-19 patients.
  • We have been encouraged by the lenzilumab efficacy and safety data demonstrated in the compassionate use series in COVID-19 patients and are thrilled that NIH selected lenzilumab to be part of its Big Effect Trial, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen.
  • With data from the BET and our ongoing Phase III study, we will have data from approximately 500 hospitalized COVID-19 patients.

Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS

Retrieved on: 
Tuesday, July 21, 2020
Medical specialties, Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Acute respiratory distress syndrome, Intensive care medicine, Respiratory physiology, Coronavirus disease, Cytokine, Lenzilumab, COVID-19 drug repurposing research

The proof-of-concept, randomized, multicenter, double-blind, placebo-controlled trial will enroll approximately 82 subjects hospitalized with COVID-19 ARDS.

Key Points: 
  • The proof-of-concept, randomized, multicenter, double-blind, placebo-controlled trial will enroll approximately 82 subjects hospitalized with COVID-19 ARDS.
  • As the first and only fully human anti-LIGHT monoclonal antibody, we believe CERC-002 has the potential to treat patients hospitalized with COVID-19 ARDS.
  • The data suggest that LIGHT might play a key role in cytokine storm that leads to ARDS.
  • It offers the potential to treat cytokine storm-induced COVID-19 ARDS in the near-term and broader ARDS indication beyond.

FDA clears Abivertinib for Phase 2 safety and efficacy study in hospitalized patients with moderate to severe COVID-19

Retrieved on: 
Monday, July 20, 2020
Medical specialties, Immunology, Clinical medicine, Medicine, Cytokines, Interleukins, Cytokine release syndrome, Cytokine, Inflammatory cytokine, Tumor necrosis factor, Interleukin 1 beta, Lenzilumab

Due to this effect, it has shown potent immunomodulatory activities in vitro by inhibiting key pro-inflammatory cytokine production, including IL-1beta, IL-6 and TNF-alpha.

Key Points: 
  • Due to this effect, it has shown potent immunomodulatory activities in vitro by inhibiting key pro-inflammatory cytokine production, including IL-1beta, IL-6 and TNF-alpha.
  • These cytokines are associated with cytokine release syndrome (CRS) or cytokine storm and COVID-19 disease progression with poor outcomes in patients with acute respiratory distress syndrome (ARDS).
  • Abivertinib has been studied in over 600 patients worldwide in various oncologic indications, including one registration trial in non-small cell lung cancer.
  • RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.

Humanigen Appoints Senior Executives to Management Team

Retrieved on: 
Tuesday, July 7, 2020
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Monoclonal antibodies, Medical specialties, Cytokines, Branches of biology, Medicine, Immunology, Lenzilumab, Granulocyte-macrophage colony-stimulating factor, Cytokine, Colony-stimulating factor, Interleukins, Namilumab

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.
  • All three positions report to Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen.
  • He is also the founder of Black Horse Capital with decades of biotechnology investment experience.
  • We are pleased that both Dr. Chappell and Mr. Tousley, who have previously operated in interim capacities with the Company, have joined us as full-time members of the Humanigen team, stated Dr. Cameron Durrant.

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 31, 2020
Health, Biotechnology, Branches of biology, Cytokines, Growth factors, Granulocyte-macrophage colony-stimulating factor, Colony-stimulating factor, Immune system, Monoclonal antibodies, Sargramostim, Macrophage colony-stimulating factor, Macrophage, Lenzilumab, Filgrastim

The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 25 molecules.
  • The latest report Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts.

Granulocyte Macrophage Colony Stimulating Factor, Pipeline Review, H2 2019 - Amgen Inc, Seagull Labs Pvt Ltd & Cold Genesys Inc - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Health, Pharmaceutical, Branches of biology, Cytokines, Growth factors, Granulocyte-macrophage colony-stimulating factor, Colony-stimulating factor, Immune system, Monoclonal antibodies, Sargramostim, Macrophage colony-stimulating factor, Macrophage, Lenzilumab, Namilumab

The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 25 molecules.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts.
  • The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Tuesday, December 10, 2019
RTT, Janus kinase inhibitor, Cancer, Acute myeloid leukemia, Chronic myelomonocytic leukemia, Leukemia, Monocytic leukemia, CMML, Oncology, Lenzilumab

The presentations are now available on the Stemline website, www.stemline.com , under the Scientific Presentations tab.

Key Points: 
  • The presentations are now available on the Stemline website, www.stemline.com , under the Scientific Presentations tab.
  • These data support further evaluation of tagraxofusp in MF, not only as single agent but potentially in combination with Jak inhibitors.
  • ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).
  • Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.

Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

Retrieved on: 
Friday, December 6, 2019
RTT, Cancer, Acute myeloid leukemia, Chronic myelomonocytic leukemia, Monocytic leukemia, CMML, Tumors of the hematopoietic and lymphoid tissues, Medical specialties, Neoplasms, Leukemia, Lenzilumab, Janus kinase inhibitor

ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).

Key Points: 
  • ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).
  • BPDCN is an aggressive hematologic malignancy with historically poor outcomes and an area of unmet medical need.
  • Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.
  • ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML).

Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

Retrieved on: 
Tuesday, October 8, 2019
RTT, Acute myeloid leukemia, Cancer, Chronic myelomonocytic leukemia, Monocytic leukemia, CMML, Tumors of the hematopoietic and lymphoid tissues, Medical specialties, Neoplasms, Leukemia, Lenzilumab, Janus kinase inhibitor

ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).

Key Points: 
  • ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).
  • BPDCN is an aggressive hematologic malignancy with historically poor outcomes and an area of unmet medical need.
  • Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.
  • ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML).